Lake Street initiated coverage on Pulmonx with a new price target
$LUNG
Medical/Dental Instruments
Health Care
Lake Street initiated coverage of Pulmonx with a rating of Buy and set a new price target of $12.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/10/2025 | $17.00 | Buy | D. Boral Capital |
| 12/11/2024 | $17.00 → $7.50 | Buy → Neutral | Citigroup |
| 6/4/2024 | $12.00 | Buy | Lake Street |
| 2/23/2024 | $16.00 → $14.00 | Overweight → Equal Weight | Wells Fargo |
| 9/5/2023 | $18.00 | Buy | Craig Hallum |
| 2/27/2023 | $10.00 → $15.00 | Equal Weight → Overweight | Wells Fargo |
| 1/3/2023 | $8.00 | Neutral → Underperform | BofA Securities |
| 12/12/2022 | $14.00 → $10.00 | Neutral → Buy | Citigroup |
REDWOOD CITY, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the company will be presenting at the Goldman Sachs 46th Annual Global Health Care Conference in Miami on Wednesday, June 11, 2025, at 7:00 AM PT / 10:00 AM ET. A live and archived webcast of the presentation will be available on "Investors" section of the Pulmonx website at https://investors.pulmonx.com/. About Pulmonx Corporation Pulmonx Corporation (NASDAQ:LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx's Zephyr®
REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx") a global leader in minimally invasive treatments for severe lung disease, today announced the company will be presenting at the Bank of America Securities 2025 Health Care Conference in Las Vegas on Wednesday, May 14, 2025, at 9:35 AM PT / 12:35 PM ET. A live and archived webcast of the presentation will be available on "Investors" section of the Pulmonx website at https://investors.pulmonx.com/. About Pulmonx CorporationPulmonx Corporation (NASDAQ:LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx's Zephyr® Endobronchial Va
REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter of 2025 ended March 31, 2025. Recent Highlights Achieved worldwide revenue of $22.5 million in the first quarter of 2025, a 20% increase over the same period last year and an increase of 21% on a constant currency basisDelivered $8.3 million in international revenue in the first quarter of 2025, representing 39% year-over-year growth and an increase of 43% on a constant currency basisDelivered $14.2 million in U.S. revenue in the first quarter of 20